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ABSTRACT
METHYLGLYOXAL INFLUENCES DEVELOPMENT OF CAENORHABDITIS
ELEGANS VIA HETEROCHRONIC PATHWAY
May 2017
JIAYING WANG
B.S., ZHEJIANG UNIVERSITY OF TECHNOLOGY
M.S, UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Yeonhwa Park

Methylglyoxal is a highly reactive dicarbonyl compound, which is widely
distributed in food products and beverages, and is particularly high in Manuka honey. In
addition to its antibacterial effects, methylglyoxal is also known as a major precursor of
advanced glycation end products (AGEs), that produces altered macromolecules (such as
proteins and DNA), leading to abnormal physiological changes. However, the effects of
methylglyoxal on development is unclear. Thus, this study aimed to determine the role of
methylglyoxal in this aspect using Caenorhabditis elegans (C. elegans). Treatment of
methylglyoxal at 0.1 mM and 1 mM for 48 h significantly inhibited development of C.
elegans and reduced pumping rate. Activity, measured by moving speed, was increased
with 0.1 mM methylglyoxal, but reduced with 1 mM methylglyoxal. Lifespan of C.
elegans was not influenced by methylglyoxal at 0.1 mM, but was shortened at 1 mM
Treatment methylglyoxal on the mutant, lin-41, which has a precocious phenotype, could
alleviate the implication on wild-type worms. These results suggested that methylglyoxal
significantly influenced the development of C. elegans through the heterochronic
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pathway.
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CHAPTER 1
INTRODUCTION
Methylglyoxal is the natural active component of Manuka honey, well known for its
antibacterial function (Degen et al., 2012). However, it is also reported to be associated
with diseases including diabetes, atherosclerosis, and neurological disorders (Vistoli et al.,
2013). Previous in vitro research found that methylglyoxal exhibited an autoxidative
character, which could generate reactive oxygen species (ROS) in the mitochondria, and
it is susceptible to alter the structure and functions of macromolecules, such as protein
and nucleotides (Lo et al., 1994; Singh et al., 2001). Animal studies further investigated
the effects of methylglyoxal in biological system. Although there were inconsistent
results of no effects or anti-cancer effects of methylglyoxal in vivo, the majority of results
concluded that methylglyoxal could induce weight-loss, inactivity, certain types of
cancers, or even death in a dose-dependent manner (Dakin and Dudley, 1913; Sjolemma
and Seekles, 1926; Nagao et al., 1986; Kalapos et al., 1991; Choudhary et al., 1997; Golej
et al., 1998). In addition, aging and neurological disorders induced by methylglyoxal are
the most investigated problems and several pathways in biological system regulated by
methylglyoxal metabolism were previously identified (Bonifati et al., 2003; Morcos et al.,
2008;Lee et al., 2012). However, to our best knowledge, there are no reports on effects of
methylglyoxal in the animal development. Therefore, we explored the effect of
methylglyoxal on development and determined the underlying mechanism.
Caenorhabditis elegans is an animal model with a short lifespan of about 21 days
(Leung et al., 2008). The development time of C. elegans only requires 48 h after
hatching at 20ºC (Leung et al., 2008). C. elegans is the first animal to have its genome
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completely sequenced, and more than 65% of the genes associated with human disease
are conserved (Kaletta and Hengartner, 2006). Thus, we choose this model to conduct the
current project.

2

CHAPTER 2
LITERATURE REVIEW
2.1. Methylglyoxal
2.1.1. Introduction
Methylglyoxal is a naturally occurring component of Manuka honey. It is a
commercial factor used for classification of premium honey products as the so-called
Unique Manuka Factor (UMF), based on in vitro anti-microbial assays (Mavric et al.,
2008). It is also known to be one of the most important components in the formation of
advanced glycation end products (AGEs) (Shinohara et al., 1998), which is associated
with diseases, such as diabetes, atherosclerosis, and neurological disorders (Vistoli et al.,
2013). Methylglyoxal is a yellowish, clear, and water-soluble liquid at room temperature,
and it is also known as pyruvaldehyde, acetyl formaldehyde, or propanedione (Figure 1).
It contains two carbonyl groups (C=O): an aldehyde and a ketone. Therefore, it is reactive
because aldehyde is readily oxidized to carboxylic acids (Corey et al., 1968).

Figure 1. Methylglyoxal chemical structure

2.1.2. Methylglyoxal formation
The origin of methylglyoxal can be separated into exogenous, from food and
beverages, and endogenous, from enzyme-catalyzed and spontaneous reaction. Overall
levels of methylglyoxal are a balance between exogenous and endogenous formation and
elimination of methylglyoxal in the biological system. There are a great number of
publications reporting the effects of methylglyoxal in the biological system in past
3

decades.
2.1.2.1. Exogenous sources
Except for honey, its only natural source, methylglyoxal can be formed in many
food products and beverages derived from carbohydrates, amino acids, lipids, and
microorganisms during food processing, cooking, and storage. Average levels of
methylglyoxal in food are summarized in Table 1.
It is known that the retro-aldol condensation and autoxidation of sugar results in
methylglyoxal, with higher levels found in monosaccharides than disaccharides. As
mentioned, honey (Table 1) is a great source of methylglyoxal (0.4 – 5.4 mg/kg) due to
simple sugar degradation during storage (Weigel et al., 2004). In addition, the Maillard
reaction, which is a reaction between amino acids and reducing sugars, can produce
methylglyoxal (Martins et al., 2003). As known in the Maillard reaction, temperature
contributes significantly to methylglyoxal formation (Martins et al., 2003). Thirdly,
decomposition of different lipids during food storage and processing could generate
methylglyoxal in food samples (Fujioka and Shibamoto, 2004). Furthermore,
photodegradation of lipids and related compounds yield methylglyoxal as a degradation
product (Niyati-Shirkhodaee and Shibamoto, 1993). Lastly, methylglyoxal can be formed
by microorganisms during fermentation processing, such as alcoholic drinks and dairy
products. Methylglyoxal is synthesized by Saccharomyces cerevisiae during alcoholic
fermentation as well as by Oenococcus oeni (Leuconostocoenos) during malolactic
fermentation (Yadav et al., 2005).
2.1.2.2. Endogenous source
In addition to food, methylglyoxal can be formed in biological systems
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endogenously. Both enzymatic and non-enzymatic pathways have been identified for
endogenous methylglyoxal formation (Vander Jagt and Hunsaker, 2003). Enzymatic
pathways include reactions involved in glycolytic bypass, acetone metabolism, and amino
acid breakdown (Cooper, 1984; Kalapos, 1999; Ko et al., 2005). Non-enzymatic
pathways include acetol autoxidation, lipid peroxidation and others (Nemet et al., 2006).
Table 1 Methylglyoxal concentration of some food
Methylglyoxal
concentration
(mg/kg)

Reference

Sweetened cola (sucrosesweetened)

0.007 to 0.32

(Tan et al., 2008)

Sweetened cola (high fructose corn
syrup-sweetened)

0.23 to 1.4

(Tan et al., 2008)

Fruit juice

0.05

(Degen et al., 2012)

Fermented beverages (yogurt,
alcoholic beverages, and soy sauce)

0.02-7.6

(Degen et al., 2012)

Jams, jellies and sweeteners

4

(Degen et al., 2012)

Coffee

23

(Degen et al., 2012)

Bread and cookies

210

(Degen et al., 2012)

Commercial honey

0.4-5.4

(Degen et al., 2012)

Manuka honey

740

(Mavric et al., 2008)

Food or beverage

2.1.2.2.1. Glycolytic Bypass
Glycolytic bypass is the major pathway of methylglyoxal formation endogenously,
and is catalyzed by methylglyoxal synthase (Chakraborty et al., 2014). If there is too
much sugar, one of the intermediates of glycolysis, glyceraldehyde-3-phosphate will be
converted to dihydroxyacetone phosphate by triosephosphate isomerase, and then
subsequently converted to methylglyoxal by methylglyoxal synthase (Ahmed et al.,
2003a). It has been proven that increased concentration of dihydroxyacetone phosphate is
5

associated with increased levels of methylglyoxal (Ahmed et al., 2003a).
2.1.2.2.2. Acetone Metabolism
Diabetes is known to have high levels of ketone bodies and among them,
acetoacetate is regarded as a characteristic feature of diabetes (Kupari et al., 1995; Veech,
2004). Acetoacetate is converted to acetone, then subsequently to hydroxyacetone by
Cytochrome P450 and acetol monooxygenase, respectively. The latter is oxidized to
methylglyoxal (Rabbani et al., 2016). Thus, it is known that diabetes has higher levels of
methylglyoxal.
2.1.2.2.3. Amino Acid Breakdown
Another non-glycolytic formation of methylglyoxal is from amino acid breakdown,
particularly from L-threonine and L-glycine. L-Threonine is initially oxidized by
threonine dehydrogenase into oxobutyrate, then to aminoacetone (Shimizu et al., 2005).
L-Glycine is converted to aminoacetone by acetyl aminoacetone synthase with CoA.
Methylglyoxal is the end product of aminoacetone degradation, which is catalyzed by
amino oxidase (Shimizu et al., 2005).
2.1.3. Methylglyoxal elimination
Methylglyoxal can be eliminated by four enzymes: the glyoxalase system, aldose
reductase (ALRs), aldehyde dehydrogenase (ADHs), and 2-oxoaldehyde dehydrogenase
(2-ODHs) (Nemet et al., 2006).
The glyoxalase system comprises two enzymes; glyoxalase I and glyoxalase II
(Thornalley, 1990). This is the major enzyme system for the elimination of methylglyoxal.
Methylglyoxal is non-enzymatically converted to hemithioacetal with glutathione and
subsequently catalyzed by glyoxalase I to S-D-Lactoylglutathione (Thornalley, 1995). S-
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D-lactoylglutathione is converted to D-lactate by glyoxalase II, and further metabolized

to pyruvate by 2-hydroxyacid dehydrogenase at the mitochondria (Thornalley, 1996).
Apart from the glyoxalase system, aldose reductases could convert methylglyoxal
into acetol and subsequently reduce it to propanediol (Vander Jagt and Hunsaker, 2003).
In addition, betaine aldehyde dehydrogenase and 2-oxoaldehyde dehydrogenases are
known to catalyze methylglyoxal to pyruvate (Vander Jagt and Hunsaker, 2003).
2.1.4. Methylglyoxal research in vitro
(Kisch, 1932) reported that methylglyoxal decreased oxygen consumption in Jensensarcoma cells. (Thornalley et al., 1984) found that methylglyoxal was autoxidative,
generated reactive oxygen species (ROS), modified mitochondrial proteins, and led to
apoptosis of rat osteoblasts. However, methylglyoxal was cytotoxic to rat hepatocytes
even under anaerobic conditions, which suggested that the autoxidation of methylglyoxal
cannot explain its toxicity completely (Kalapos et al., 1993; Chan et al., 2007).
Methylglyoxal is susceptible to react irreversibly with protein, nucleotides, and basic
phospholipids, which is verified in in vitro experiments (Thornalley, 1995; Ahmed et al.,
2003b). This process is called dicarbonyl glycation and the adducts formed are AGEs
(advanced glycation end-products). AGEs are known to have altered macromolecule
structure and functions, and to be associated with complications of diabetes,
atherosclerosis, and altered immune response (Chakraborty et al., 2014; Thornalley et al.,
1999).
Methylglyoxal targets arginine residues, forming hydroimidazolone adducts (MGH1), which is one of the major AGEs in physiological systems (Rabbani and Thornalley,
2012). There are also minor lysine-derived AGEs: such as CEL [Nε-(1-carboxyethyl)
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lysine], argpyrimidine, and trace levels of MOLD (MG-derived lysine dimer cross-link)
(Rabbani and Thornalley, 2012). Protein adducts bind specifically to cell-surface
receptors, which is a specific receptor for AGEs, to activate cell dysfunction (Bierhaus et
al., 2005). Methylglyoxal also forms DNA adducts in physiological systems. The major
adduct is an imidazopurinone MGdG {3-(2-deoxyribosyl)-6,7-dihydro-6,7-dihydroxy6/7-methylimidazo-[2,3-b] purine-9(8) one} and a minor adduct CEdG [N2-(1carboxyethyl)-deoxyguanosine], which were associated with DNA instability and
resulted in mutagenesis (Thornalley and Rabbani, 2010).
2.1.5. Methylglyoxal research in vivo
The research of methylglyoxal in vivo is summarized in Table 2. The first in vivo
experiment of methylglyoxal reported that the subcutaneous injection of this compound
had no effects on rabbits (Dakin and Dudley, 1913). (Apple and Greenberg, 1968)
demonstrated methylglyoxal had an anti-cancer effect in mice. However, the reduced
psychomotoric activity of methylglyoxal was first reported in 1926 as the adverse effect
of methylglyoxal in rabbits (Sjolemma and Seekles, 1926). Others reported that
methylglyoxal injected rats were found to develop skin cancers (Nagao et al., 1986). The
acute lethal dose of methylglyoxal was 800 mg/kg body weight, while a lower dose of
methylglyoxal led to a decrease of liver weight, inactive and/or irregular muscle
movement (Kalapos et al., 1991; Choudhary et al., 1997). Oral administration of
methylglyoxal targeted kidneys, accumulating methylglyoxal collagen that thickened
glomerular basement membrane with an obligatory morphological change (Golej et al.,
1998).
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Table 2. Methylglyoxal research in vivo
Time

Animal
models

Treatment

Methylglyoxal
dose

Conclusion

Reference

1913

Rabbits

Subcutaneous
injection

Unknown

No effects

(Dakin and
Dudley,
1913)

1926

Rabbits

Subcutaneous
injection

Unknown

Without appetite and
depressed

(Sjolemma
and
Seekles,
1926)

1968

Male
swiss
albino
mice

Unknown

Unknown

Anti-cancer effects
on variety of cancers

(Apple and
Greenberg,
1968)

1986

Male & Skin injection
female
fischer
344 rats

2 mg/animal

Developed cancers

(Nagao et
al., 1986)

1991

Male
CFLP
mice

Intraperitoneal
injection

Unknown

Slowed movement
and ataxy

(Kalapos et
al., 1991)

1991,
1997

Male
swiss
albino
mice

Intraperitoneal
injection

800 mg/kg
body weight

Lethal within 4 h

(Kalapos et
al., 1991;
Choudhary
et al., 1997)

1991,
1997

Male
swiss
albino
mice

Intraperitoneal
injection

Less than 800
mg/kg body
weight

Decreased liver
weight after 24 h

(Kalapos et
al., 1991;
Choudhary
et al., 1997)

1991

Male
swiss
albino
mice

Intraperitoneal
injection

400 mg/kg
body weight

Slight histological
changes in livers
(vacuole formation
in the centrilobular
areas)

(Kalapos et
al., 1991;
Choudhary
et al., 1997)

1998

Female
OF-1
mice

Oral
administration

50 mg/kg body Collagen
weight
accumulation in
kidneys; glomerular
basement membrane
thickening
9

(Golej et
al., 1998)

2.1.6. Strategies for minimizing methylglyoxal
Based on the information above, strategies for prevention of methylglyoxal toxicity
could be by: (a) prevention of methylglyoxal formation, (b) scavenging of methylglyoxal
directly, and (c) enhancing the expression of enzymes of methylglyoxal elimination,
particularly glyoxalase-1 (Rabbani et al., 2016). First, the formation of methylglyoxal can
be reduced by a high dose of thiamine supplementation by decreasing the activity of
triosephosphate isomerase, a key enzyme for methylglyoxal production. Secondly,
scavengers, such as aminoguanidine, phenacylthiazolium derivatives, and arginine-rich
peptides, can be used to scavenge methylglyoxal directly. However, it is not clear that
these products are without any toxic effects (Rabbani et al., 2016). Lastly, enhancing
glyoxalase-1, ALRs, and ADHs, which are the key enzymes for eliminating
methylglyoxal, can reduce methylglyoxal levels. Based on reports that the transcription
factor, Nrf2 (nuclear factor-erythroid 2-related factor-2), regulates the above enzymes
and is downregulated during aging, it is possible that by targeting Nrf2, elimination of
methylglyoxal can be enhanced (Rabbani et al., 2016).

2.2. Caenorhabditis elegans
2.2.1. General characteristics of C. elegans
C. elegans is a small (1~1.5 mm as an adult), eukaryotic, multi-organ, and freeliving nematode found worldwide. C. elegans is easily cultivated on agar plates and
typically feeds on non-pathogenic Escherichia coli (E. coli). The body and neural
circuitry is anatomically simple, with approximately 1,000 somatic cells and 300 neurons
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(Giles and Rankin, 2009; Dimitriadi and Hart, 2010). The transparent body of this worm
makes it easy to view the tissue in all stages of development under an optical microscope.
Normally, a wild-type C. elegans has a short lifespan of about 21 days, and reaches
adulthood within 38~46 h after hatching at 20◦C. C. elegans produces large broods of 300
progenies and each hermaphrodite has two ovaries, oviducts, a cavity for storing sperm
(spermatheca), and a uterus (L’Hernault, 2009). Most importantly, C. elegans is the first
animal to have its genome completely sequenced, and more than 65% of the genes
associated with human disease are conserved in the worm (Greer et al., 2008). In addition,
C. elegans exhibits very complicated functions varying from feeding to locomotion
suggesting further application for in vivo research.
2.2.2. C. elegans as an animal model for development research
C. elegans has been used in studies for cell biology, genetics, and neurobiology
since 1965. Between 1970 and 1980, the complete cell lineage of this worm, from the
fertilized egg to adult, was characterized by laser ablation and microscopy (Sulston et al.,
1983). (White et al., 1986) constructed the entire nervous system by electron microscopy
and serial sectioning, and (Coulson et al., 1991) started to work on genetic and genomic
data collection. Bioassays to assess the impact of inherent or environmental changes on C.
elegans can be carried out through different endpoints. These endpoints can be grouped
according to their effects on biological parameters, such as lethality, growth, locomotion,
reproduction, etc. It is also possible to use molecular markers to determine oxidative
stress, changes in gene or protein expression, DNA damage, or green fluorescence
protein (GFP) expression (Tejeda-Benitez and Olivero-Verbel, 2016).
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2.2.2.1. Physiological parameters of C. elegans
Among worms’ development parameters, body length of synchronous worms before
and after exposure can be used to evaluate the effect of a compound in the growth of the
nematode. The developmental stage of C. elegans can be determined by: L1, four or
fewer gonad cells, L2, over four gonad cells which have begun to spread along the length
of the animal, L3, extension of the gonad, and vulvae morphogenesis has started, L4, a
dorsal rotation of the gonad, and adults, observable eggs (Helmcke et al., 2009). The
deterioration of the neural system during development can be evaluated by locomotion,
which includes head thrash, body bend frequency, and basic movements (Yu et al., 2013).
A head thrash is defined as a change in the direction of bending in the body, observed as
a change in direction of the upper pharynx along the Y-axis, assuming that the nematodes
are moving along the X-axis. The body bend frequency refers to the frequency of
oscillations between adjacent body segments. The basic movement is measured as
average speed of worm crawling or swimming (Yu et al., 2013). Brood size is the
endpoint of development and is used to evaluate the reproduction of the nematodes.
Moreover, the gonad size, obtained by image analysis under a microscope, has been
utilized to evaluate the effects on reproductive organs and the rate of egg laying, which
means the number of eggs laid in 1 h is a biomarker of reproduction (Jadhav and Rajini,
2009;Shashikumar and Rajini, 2010;Wu et al., 2011). The lifespan is defined as the
period between the L4 larval stage and death. At 20°C, the wild type C. elegans has an
average lifespan of around 2–3 weeks (Yunhui et al., 2009;Shen et al., 2009;Wang et al.,
2010;Zhuang et al., 2014).
2.2.2.2. Development pathway of C. elegans
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After embryogenesis, C. elegans develops through four larval stages (L1–L4) before
reaching sexual maturity. The proper temporal control of stage-specific events of cell
division, cell behavior, and differentiation through four larval stages are controlled by the
heterochronic pathway, which is comprised by a number of microRNA and protein
regulators (Figure 2). The precise scheduling for the stage-specific events and temporal
controls of cell division, differentiation, and morphogenesis is regulated by a complex but
organized schedule of heterochronic gene activities for animal normal development.
Adult stage is also regulated by the heterochronic pathway to exit the cell cycle, fuse with
neighboring hypodermal seam cells, and generate cuticle alae (Sulston and Horvitz, 1977;
Reinhart et al., 2000). However, improper development can result in either retarded or
precocious development, by repeating early developmental events or by expressing late
developmental events at early stages, respectively.

Figure 2. Expression of some heterochronic genes during larval development (Lee et al., 1993; Rougvie
and Ambros, 1995; Slack et al., 2000) .

2.2.2.2.1. lin-14
The gene lin-14 encodes a novel protein, LIN-14, in C. elegans, whose activity is
required for the timings of vulva cell group division during postembryonic development
(Lee et al., 1993). The normal L1 stage requires a high level of lin-14 activity and the
execution of L1 stage to later stages depends essentially on the decrease of lin-14
expression. In addition, lin-14 acts with lin-4 to govern L1 cell fates, and then interacts
13

with lin-28 to regulate L2 developmental events (Ambros and Horvitz, 1984). The lin-14
null (0) mutant misses the expression of L1 specific events, thus becoming precocious
compared to the normal developmental program. In the contrary, lin-14 gain-of-function
mutant displays a retarded phenotype (Ambros and Horvitz, 1984).
2.2.2.2.2. lin-4
The lin-4 encodes a small non-coding temporal RNA (stRNA) and is a critical gene
in the early stages of development in diverse cell types of C. elegans (Lee et al., 1993).
Expression of lin-4 begins at the end of the L1 larval stage and increases to highest levels
in adult animals (Ambros and Horvitz, 1984). Repression translation of the lin-14 and
execution L1 stage is the function of lin-4 (Ambros and Horvitz, 1984). Thus, lin-4 lossof-function mutation, lin-4(e972), displays reiterations of L1 events at late developmental
stages (Ambros and Horvitz, 1984).
2.2.2.2.3. lin-28
For L2 stage specific developmental events, the heterochronic gene, lin-28, plays a
critical role. In addition, LIN-28 is an RNA binding protein, best known for regulating
the maturation of the microRNA let-7 (Rougvie and Ambros, 1995;Reinhart et al.,
2000;Pepper et al., 2004). However, lin-28 expression was not detectable after the L3
stage. Several researches confirmed that the function of lin-28 at the L2 stage was a
premise for larva-to-adult transition, which means lin-28 interacted with other
heterochronic genes to affect the larval-to-adult transition (Rougvie and Ambros,
1995;Reinhart et al., 2000;Pepper et al., 2004). Thus, lin-28 loss-of-function mutant not
only skips the L2 stage seam cell proliferative program, but also causes precocious
execution of the larva-to-adult transition, which presents the phenotype of lateral

14

hypodermal seam cells ceasing division, differentiation, and adult alae production
(Ambros and Horvitz, 1984).
2.2.2.2.4. let-7 family microRNAs
The let-7 family microRNAs comprise let-7, a critical regulator of developmental
timing events at the larval-to-adult transition, and three other microRNA genes: mir-48,
mir-84, and mir-241, which regulate L2-to-L3 developmental timing decisions. The
retarded behaviors, like extra seam cell divisions, could be found in diverse cell types
from the L2 to L3 transition in double mutants mir-48: mir-241, mir-48: mir-84, and
triple mutants (Abbott et al., 2005). However, normal phenotype was observed in the
singly mutant worms with deletions of mir-48, mir-84, or mir-241 and the double mutant
mir-84: mir-241.
The let-7 functions as a temporal switch between larval and adult fates since the
expression of let-7 is only detected at L4 and adult stages. Thus, the let-7 loss-of-function
mutant reiterates larval patterns of hypodermal cell division during the L4-to-adult
transition. Besides, it undergoes a supernumerary molt to an extra stage, L5, before adult.
In contrast, the overexpression of let-7 causes precocious adult fates during larval stages,
which means hypodermal cells exit the cell cycle ahead of time.
2.2.2.2.6. lin-41
The lin-41 encodes a RING-finger B-box Coiled-coil (RBCC) protein and is
negatively regulated by the let-7 microRNA during L4 and adult stages (Solomon et al.,
2008). In addition, lin-41 represses lin-29 during late larval stages, which prevents
terminal differentiation of hypodermal seam cells. Thus, lin-41 loss-of-function mutants
display premature phenotypes from the L3 larval stage that seam cells adopt the adult fate
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to secrete alae ahead of time, but does not affect L1 and L2 stage fates (Reinhart et al.,
2000; Solomon et al., 2008).
2.2.2.2.7. lin-29
The lin-29, a zinc-finger transcription factor, which regulates adult-specific patterns
of cell lineage and cell differentiation, acts as a downstream of heterochronic genes, let-7
and lin-41 (Rougvie and Ambros, 1995; Reinhart et al., 2000). Furthermore, lin-29 is the
most direct known regulator of the larval to adult transition in C. elegans (Rougvie and
Ambros, 1995). Thus, lin-29 activity is essentially required for the execution of almost all
aspects of the larval to adult transition, particularly for the terminal differentiation of the
lateral hypodermal seam cells and the formation of the adult cuticle (Rougvie and
Ambros, 1995). In the lin-29 loss-of function mutant, the seam cells continue to
synthesize a larval-specific cuticle lacking adult-specific alae, which means the animal
undergoes supernumerary molts (Ambros and Horvitz, 1984). Interestingly, both the lin29 loss-of-function mutant and the let-7 loss-of-function mutant display a retarded
phenotype, but the former repeats the cell cycles in the L4-stage indefinitely, while let-7
loss-of-function mutants only repeat once, which indicates lin-29 displays a stronger
function in the heterochronic pathway than let-7 (Slack et al., 2000).

2.3. Methylglyoxal Research in C. elegans
The activity of glyoxalase-1 is markedly reduced with age. However, in aging,
methylglyoxal level, methylglyoxal-derived adducts, and oxidative stress markers, such
as carboxymethyllysine (CML) and 3-nitrotyrosine, increase dramatically (Morcos et al.,
2008). As reported, over-expression of the glyoxalase-1 ortholog, CeGly 1, could prolong
C. elegans lifespan by decreasing modification of mitochondrial protein and ROS
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production (Morcos et al., 2008).
In humans, protein deglycase, DJ-1, is expressed to protect cells from oxidative and
exert neuroprotection against Parkinson's Disease (Bonifati et al., 2003; Lee et al., 2012).
In C. elegans, cDJR-1.1, a DJ-1 ortholog expressed primarily in the intestine, when
lacking decreased 71% of the enzyme activity for methylglyoxal elimination; cDJR-1.2,
another DJ-1ortholog, expressed primarily in the head region and leading to the
significant degeneration of the dopaminergic neurons, when lacking decreased 28% of
the enzyme activity for methylglyoxal elimination (Bonifati et al., 2003;Lee et al., 2012).
Thus, these findings imply that cDJR-1.1 and cDJR-1.2 are important in methylglyoxal
elimination, which could protect worms from methylglyoxal.
At present, the methylglyoxal research in C. elegans is limited to aging and
neurological disorders. As an ideal model for development study, C. elegans is a great
tool to investigate the interaction between methylglyoxal and development.

2.4. Conclusion
Methylglyoxal, as an active carbonyl compound, can be produced inherently or
elevated by exogenous sources. In order to minimize its toxicity on aging, development,
and the nervous system, there are endogenous elimination systems to keep the normal
metabolic activity. According to previous studies, glyoxalase-1 and DJ-1 are reported as
essential pathways in methylglyoxal regulation with aging and neurological issues,
respectively. As for development, C. elegans could be a great model to be used for its
completed understood genome sequence and heterochronic system. This review
elucidates the mechanism of methylglyoxal in development of C. elegans.
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CHAPTER 3
MATERIALS AND METHODS
3.1. Strains
The C. elegans strain N2 was used as the wild-type worm. The N2 strain, mutant lin41(ma104) I and Escherichia coli (E. coli) OP50 were obtained from the Caenorhabditis
Genetics Center (CGC), University of Minnesota, USA.
3.2. Chemicals
Methylglyoxal aqueous solution was purchased from MP Biomedicals, LLC (Solon,
OH). 5-fluoro-2′-deoxyuridine (FUdR) was purchased from Sigma-Aldrich Co. (St. Louis,
MO). Household bleach for synchronization of worms was purchased from a local store
(The Clorox company, Oakland, CA). Other chemicals were purchased from Thermo
Fisher Scientific Inc. (Pittsburgh, PA).
3.3. Worm maintenance
Synchronized worms were prepared by placing adult worms on a nematode growth
media (NGM) plate containing a lawn of E. coli OP50. After removing the worm bodies
using freshly prepared bleach solution, each synchronized egg was transferred to a Scomplete solution in 15 ml conical tubes. When the eggs hatched, concentrated E. coli
OP50 was added with 0.1 mM or 1 mM methylglyoxal, respectively. All C. elegans
strains were raised at 25C.
3.4. Growth rate assay
For each treatment group, 50 worms were selected randomly and paralyzed with 10
mM NaN3. The worms were transferred onto NGM plates without a bacterial lawn and
the developmental stages were identified under an optical microscope. The growth rates
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were measured as the population ratio of worms at different developmental stages.
3.5. Pumping rate assay
For each treatment, 12 worms were randomly selected and placed on NGM plates
with a thin layer of E. coli OP50. The number of nematodes’ pharynx contractions was
counted for 1 min using an optical microscope. Experiments were carried out in
triplicates.
3.6. Body size and activity determination
For each treatment, 50 worms were randomly selected and placed on low-peptone
NGM plates. E. coli OP50 were seeded 5 min before tracking. Then worms were allowed
to acclimate and move for 15 min before video recording. A 1-min recording (7.99
frames per second) was captured by WormLab Video Capture System (Version 3.1.0,
MBF Bioscience, Williston, VT, USA). The average moving speed and the body size
(length and width) were analyzed by WormLab (Version 3.1.0, MBF Bioscience,
Williston, VT, USA).
3.7. Lifespan assay
Lifespan analysis was carried out at 25°C. Worms were treated with methylglyoxal
at 0.1 mM and 1 mM from the L4 stage, at which 120 μM 5-Fluoro-2′-deoxyuridine
(FUdR) was added in HTS Transwell®-96 well permeable plates (Corning Inc., NY). The
medium was changed twice a week. Plates were shaken for 2 min before counting and
worm viability was scored every other day until all the worms died.
3.8. Statistical analysis
All data were expressed as mean ± standard error (S.E.). Mean differences between
treated groups and controls were determined by one-way analysis of variance (ANOVA),
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followed by Dunnett’s test using the Statistical Analysis System (Version 9.4, SAS
Institute, Cary, NC). A P-value of less than 0.05 was considered significant.
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CHAPTER 4
RESULTS AND DISSCUSION
4.1. Methylglyoxal treatment significantly reduced the lifespan of C. elegans
The result (Figure 1) showed that the 1 mM methylglyoxal treatment group had a
significantly reduced maximum lifespan of 21 days, compared to the control (34 days).
Methylglyoxal at 0.1 mM did not influence the lifespan of wild-type worms. The median
lifespan was 21, 23, and 11 days in the control, 0.1 mM, and 1 mM treatment groups,
respectively. These indicated that 1 mM methylglyoxal, but not 0.1 mM, significantly
accelerated aging compared to control.

co n tro l

100

P e r c e n t s u r v iv a l

0 .1 m M M e t h y l g l y o x a l
1 m M M e th y lg y o x a l

50

0
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20

30

40

tim e (d a y )

concentration
P- value

0.1 mM versus control
Not significant

1 mM versus control
< 0.0001

1 mM versus 0.1 mM
<0.001

Figure 3. Effects of methylglyoxal on survival of C. elegans. Age-synchronized L4 C. elegans were
cultured in 96-well plates with 0, 0.1 mM, and 1 mM methylglyoxal from the first day of adulthood. The
number of survivals were recorded every other day. Around 100 worms were raised for each group.
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4.2. Methylglyoxal treatment significantly delayed the development of C. elegans
To determine whether methylglyoxal had any effects on the development of the
nematodes, the growth rate was analyzed. As shown in Figure 2, after 48 h of treatment
with methylglyoxal, 28-34% of the worms were at the L3 stage in the control and 0.1 mM
treatment groups, while this number significantly increased to 77% in the 1 mM
treatment group. In the control and 0.1 mM treatment group, 56-59% of worms reached
the L4 stage, but it was 19% in the 1 mM treatment group. These suggested that 1 mM
methylglyoxal delayed C. elegans’ development from the L3 stage.

Figure 4. Effect of methylglyoxal on the development of C. elegans. Age-synchronized L1 C. elegans were
cultured on NGM plates with 0, 0.1, and 1 mM methylglyoxal. The number of worms at each
developmental stage after 48 h was counted. Values represent means ±S.E. (n=50). ** in the L3 stage
means significantly different when 1 mM compared with the control and 0.1 mM treatment group (P<0.01).
** in the L4 stage means significantly different when 1 mM compared with the control and 0.1 mM
treatment group (P<0.01).

4.3. Methylglyoxal treatment significantly reduced body size of C. elegans
There was a significant decrease in body length when comparing the treatment
group to the control (Figure 5). The body width showed consistent results with body
length, specifically that methylglyoxal treated worms decreased worm width compared to
the control. Both 0.1 mM and 1 mM methylglyoxal reduced the body size of C. elegans.
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Importantly, 0.1 mM methylglyoxal exerted this effect on worms without inhibiting their
growth rate (Figure 4).

Figure 5. Effect of methylglyoxal on the body size of C. elegans. A: Worm length and B: worm width was
measured by WormLab software after 48 h treatments. Values represent means ±S.E.(n=50). *** means
significantly different from control (P<0.001)

4.4. Methylglyoxal treatment significantly altered locomotion behaviors of C.
elegans
After exposure to methylglyoxal for 48 h, 0.1 mM of methylglyoxal led to a
significant increase in the mean speed, while the 1 mM treatment group significantly
slowed down compared to the control (Figure 6A). However, both 0.1 mM and 1 mM
treatment groups decreased pharyngeal pumping rates significantly compared to the
control (Figure 6B). The reduction was 7% and 8% in 0.1 mM and 1 mM methylglyoxal,
respectively.
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Figure 6. Effects of methylglyoxal on the locomotion behavior of C. elegans. After treated to
methylglyoxal for 48 h from L1, A: the average moving speed was measured by WormLab software, and B:
pharyngeal pumping rate was measured under the optical microscope. Values represent means ±S.E.(n=50).
* in A means significantly different from control (P<0.05). There is a significant difference between 0.1
mM and 1 Mm treatment group in A (P<0.001). ** in B means significantly different from control
(P<0.01).

4.5. Heterochronic pathway related gene, lin-41, is involved in the effect of
methylglyoxal in C. elegans
In the lin-41 mutants, we found that the developmental period (L1 to adult) was
reduced to approximately 40 h, while the wild-type worms were approximately 48 h. It
might be because lin-41 mutant displayed their premature behaviors form the L3 stage
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(Figure 7A). Besides, the worm length reduced by 45% (Figure 7B), the average speed
reduced by 59% (Figure 7C), and the pumping rate decreased by 30% (Figure 7D)
compared to the wild-type worms. The results shown in Figure 7 indicated that there
were no significant differences on development, body size, and locomotion behaviors
among the different methylglyoxal treatment groups in the lin-41 mutants.

Figure 7. Effects of methylglyoxal on development in the lin-41 mutants. Age-synchronized L1 lin-41
worms were cultured on NGM plates with 0, 0.1, and 1 mM methylglyoxal. A: The number of worms at
each developmental stage after 40 h was counted to calculate population percentages of each larval stage. B:
worm length and C: moving speed of lin-41 mutants were measured by WormLab software when the
control group worms reached L4/young adult after 40 h treatments. D: Pharyngeal pumping rate was
counted under optical microscope. Values represents means ± S.E. (n=50 in A, B, & C, n=12 in D).
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4.6. Discussion
In the present research, methylglyoxal at 1 mM significantly decreased lifespan and
delayed development of C. elegans. Furthermore, methylglyoxal at 0.1 mM displayed
effects on worm body size and locomotion behaviors. The lin-41 mutant abolished the
effects of methylglyoxal on development, worm body size, and locomotion behaviors, at
both 0.1 mM and 1 mM, suggesting that this heterochronic pathway is a target of
methylglyoxal's effect.
In previous studies, Drosophila melanogaster upon methylglyoxal treatment
significantly reduced its maximum lifespan in a dose-dependent manner from 5 mM to 50
mM, where 10 mM of methylglyoxal reduced 48% of the median lifespan (Guelinckx et
al., 2008). However, the current study showed that 1 mM methylglyoxal reduced 33% of
the maximum lifespan of C. elegans compared to the control group, which suggested that
C. elegans is more susceptible to methylglyoxal than Drosophila melanogaster.
Locomotion is a natural behavior that the worm’s movement exhibits as an
undulatory motion produced by waves of muscular contraction and relaxation regulated
by the nervous system (Burr et al., 2004). The results of this research indicated that the
average moving speeds of methylglyoxal-treated worms depends on concentrations of the
compound. This type of response was similar to those overserved in Parkinson's disease,
which include periods of abnormally high (rigidity) and then low (bradykinesia) motor
activity. Thus, it would be important to investigate effects of methylglyoxal in the
nervous system in the future.
The control of pharyngeal pumping rate is a complex process that involves both the
pharyngeal muscle cells and neurons that innervate the pharynx. The obvious reduction
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of pumping rate by methylglyoxal could be a cause for retarded development. However,
in this research, the significant reduction of pumping rate was not consistent with the
developmental delay at 0.1 and 1 mM, which suggests that there would be at least two
distinctive pathways involved in methylglyoxal's effects on these.
Growth rate under microscopic observation is the most direct parameter of
development due to specific developmental events: the L1/L2 molt and the start of
oogenesis in young adult C. elegans. Corresponding with lifespan data, growth was
delayed significantly when the concentration of methylglyoxal was increased to 1 mM.
The current results showed both 0.1 mM and 1 mM of methylglyoxal causing significant
reductions in worm length and width. Since most of the worms (77 %) were at the L3
stage upon 1 mM treatment, compared to 28-34 % of worms at the L4 stage of control
and 0.1 mM treatment, the reduced worm sizes may result from the retarded development
stage. However, without interferencing by development delayed, low dose at 0.1 mM
methylglyoxal still exerted its effect on body sizes.
In C. elegans, lin-41 encodes a RING-finger B-box Coiled-coil-containing protein
and is involved in the heterochronic pathway, which temporally control the timing of
each larval stage (Solomon et al., 2008). The let-7 microRNAs, which takes effect on the
L2-to-L3 transition, regulates lin-41 negatively. More importantly, lin-41 represses lin-29,
the most direct regulator of the larval to adult transition in C. elegans, to prevent terminal
differentiation of hypodermal seam cells (Reinhart et al., 2000). Thus, lin-41 loss-offunction mutants would display premature phenotypes at the L3 larval stage and secrete
adult alae ahead of time, but would have normal L1 and L2 stage fates (Reinhart et al.,
2000; Solomon et al., 2008). The current study showed that lin-41 mutants abolished all
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the effects of methylglyoxal on development, suggesting that methylglyoxal delays
development through the heterochronic pathway, particularly lin-41.
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